Funder
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma. Neurooncol Adv. 2021;3:vdaa153.
2. Acar S, Nieblas-Bedolla E, Armstrong AE, Hirbe AC. A systematic review of recent and ongoing clinical trials in patients with the neurofibromatoses. Pediatr Neurol. 2022;134:1–6.
3. Welling DB. Targeted therapies in the treatment of vestibular schwannomas: current state and new horizons. Otolaryngol Clin North Am. 2023;56:543–56.
4. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. 2014;588:2743–52.
5. Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023;23:512–25.